Kovack Advisors Inc. Sells 3,229 Shares of AbbVie Inc. $ABBV

Kovack Advisors Inc. lowered its position in shares of AbbVie Inc. (NYSE:ABBV) by 21.2% in the third quarter, HoldingsChannel reports. The fund owned 11,981 shares of the company’s stock after selling 3,229 shares during the period. Kovack Advisors Inc.’s holdings in AbbVie were worth $2,774,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. boosted its position in AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares during the last quarter. Freedom Investment Management Inc. grew its stake in AbbVie by 3.1% in the second quarter. Freedom Investment Management Inc. now owns 9,877 shares of the company’s stock valued at $1,833,000 after purchasing an additional 293 shares in the last quarter. Finally, Tributary Capital Management LLC acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $566,000. 70.23% of the stock is owned by institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approves the all‑oral combination of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated CLL — a first‑in‑class, fixed‑duration regimen supported by Phase 3 AMPLIFY data. This expands AbbVie’s addressable hematology market, could drive incremental high‑margin sales and offers a differentiated product profile (time off therapy). U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Coverage noting the FDA approval frames the combo as potentially setting a new standard for slow‑growing blood cancers, highlighting improved three‑year outcomes versus chemo and the commercial upside if physicians adopt an oral, fixed‑duration approach. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: Board declared a quarterly cash dividend of $1.73/share (ex‑div April 15) — reinforces AbbVie’s income profile (Dividend King status) and supports the stock’s appeal to yield‑focused investors. AbbVie Declares Quarterly Dividend
• Positive Sentiment: VOLITE skin‑quality trial completion update suggests progress in AbbVie’s dermatology pipeline (potential incremental indications/label expansion), a longer‑term earnings catalyst if follow‑up data are positive. AbbVie’s VOLITE Skin Quality Trial Completion: What It Means for ABBV Investors
• Neutral Sentiment: Company launched a healthcare‑innovation podcast (“The Persistence Lab”) — useful for brand/ stakeholder engagement but unlikely to move near‑term fundamentals. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Neutral Sentiment: Investor pieces encouraging a reassessment of AbbVie’s post‑Humira pipeline highlight progress but are mixed on timing and magnitude of offset to Humira’s legacy revenues — suggests potential upside if execution continues but not guaranteed. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Negative Sentiment: Evercore trimmed its price target slightly (from $232 to $228) and flagged that Tremfya’s market‑share gains may not translate into strong long‑term earnings growth — this analyst caution can weigh on sentiment given AbbVie’s recent valuation and investor focus on growth after Humira. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. BMO Capital Markets restated an “outperform” rating and set a $258.00 target price on shares of AbbVie in a report on Thursday, January 15th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a research note on Tuesday, November 4th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, Scotiabank initiated coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $252.79.

AbbVie Price Performance

NYSE:ABBV opened at $224.13 on Friday. The company has a market cap of $396.12 billion, a P/E ratio of 94.97, a P/E/G ratio of 0.80 and a beta of 0.35. The firm’s fifty day moving average price is $224.01 and its two-hundred day moving average price is $221.70. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter last year, the company posted $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s dividend payout ratio is presently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.